The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer

Garg, Scot; Sarno, Giovanna; Serruys, Patrick W.; Vries, Ton de; Buszman, Paweł; Linke, Axel; Ischinger, Thomas; Klauß, Volker; Eberli, Franz R.; Corti, Roberto; Wijns, William; Morice, Marie‐Claude; Mario, Carlo Di; Geuns, Robert Jan van; Eerdmans, Pedro; Es, Gerrit Anne van; Meier, B; Jüni, Peter; Windecker, Stephan

doi:10.4244/eijv6i2a37

Cited by 50 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[13][14][15][16][17] Trials have revealed the lower rates of MACE in short-and long-term follow-up after the DP-EES implantation in comparison to the earlier generation and have introduced the DP-EES as the standard of DES, versus other design improvements. 18 Investigators have also confirmed the superiority of the BP-BES over the first-generation DES.…”

Section: Discussionmentioning

confidence: 99%

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Parsa¹,

Saroukhani²,

Majlessi³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

We compared outcomes of percutaneous coronary intervention patients who received biodegradable-polymer biolimus-eluting stents with those who received durable-polymer everolimus-eluting stents.At C oronary artery stenting is widely accepted as the treatment of choice for most cases of coronary artery disease (CAD). Implantation of the drug-eluting stents (DESs), in comparison with the bare-metal stents (BMS), has conferred better outcomes for coronary artery stenting. [1][2][3][4] Although the administration of the first-generation DES showed a higher rate of success than that of the BMS, doubts were raised over its safety because of the reported cases of late stent thrombosis and very late restenosis. 5 The link between late stent thrombosis and incomplete endothelial coverage of the stent struts caused changes in the design and materials of the platforms and polymers of the stents. 6 Randomized controlled trials and studies have revealed promising results after the implantation of the zotarolimus-and the everolimus-eluting stents, in comparison with the first-generation DES and the BMS.7-9 On the other hand, concerns about late stent failure caused by untoward reactions to the stent polymer led to the introduction of a new-generation DES in which polymers degrade after the termination of drug release. 10 In these stents, drug release lasts about 28 days and an abluminal biodegradable polymer is absorbed after 6 to 9 months, thus turning the DES into a BMS and, theoretically, averting late stent failure as a result of reaction to polymers. Trials have shown the noninferiority of the biodegradable-polymer biolimus-eluting stent (BP-BES) to the previous generations of DESs; however, only a few investigators have compared the biodegradable-polymer with the durable-polymer DES in real-world registries. 11,12 Further analysis of large and

show abstract

Section: Discussionmentioning

confidence: 99%

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Parsa¹,

Saroukhani²,

Majlessi³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

show abstract

“…More recently, alternative degradable coatings were developed to avoid a permanent polymer-mediated inflammatory stimulus on the vessel wall (48,49). However, the long-term reliability of degradable polymer coatings in accelerating re-endothelialisation and optimising vascular healing still needs to be proven.…”

Section: Simsekyilmaz Et Al Coronary Interventionsmentioning

confidence: 99%

Progress in interventional cardiology: challenges for the future

Simsekyilmaz¹,

Liehn²,

Militaru³

et al. 2015

Thromb Haemost

View full text Add to dashboard Cite

SummaryCardiovascular disease is the leading cause of death in the western and developing countries. Percutaneous transluminal coronary interventions have become the most prevalent treatment option for coronary artery disease; however, due to serious complications, such as stent thrombosis and in-stent restenosis (ISR), the efficacy and safety of the procedure remain important issues to address. Strategies to overcome these aspects are under extensive investigation. In this review, we summarise relevant milestones during the time to overcome these limitations of coronary stents, such as the development of polymer-free drug-eluting stents (DES) to avoid pro-inflammatory response due to the polymer coating or the developement of stents with cell-directing drugs to, simultaneously, improve re-endothelialisation and inhibit ISR amongst other techniques most recently developed, which have not fully entered the clinical stage. Also the novel concept of fully biodegradable DES featured by the lack of a permanent foreign body promises to be a beneficial and applicable tool to restore a natural vessel with maintained vasomotion and to enable optional subsequent surgical revascularisation.

show abstract

“…The durable polymer in first generation stents may be one of the causes of incomplete endothelisation [53]. The BIOMATRIX stent is stainless steel and elutes Biolumis, a sirolimus analogue, combined with an abluminal poly-Llactide polymer that biodegrades within six to nine months [41].…”

Section: Biolimus Eluting Stents With Biodegradable Polymermentioning

confidence: 99%

Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents

Bell

Layland

Poon

et al. 2011

Heart, Lung and Circulation

View full text Add to dashboard Cite

The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer

Cited by 50 publications

References 25 publications

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Progress in interventional cardiology: challenges for the future

Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents

Contact Info

Product

Resources

About